1343PEfficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) previously treated with 2nd-generation ALK TKIs E. Felip Font,Alice T. Shaw,Ben Solomon,T.M. Bauer,S-H.I. Ou,Shirish M. Gadgeel,R.A. Soo,T. Seto,J.S. Clancy,L.P. James,A. Abbattista,B. BesseANNALS OF ONCOLOGY(2017)引用 0|浏览10暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要